Market Currents
The FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed...
-
Tuesday, July 3, 2012, 11:24 AM ETThe FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed acquisition of Cephalon would have been anti-competitive for several generic drugs. The order requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals (PRX -0.6%), and allow PRX to sell a generic version of Cephalon's narcolepsy drug Provigil in 2012.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
